99 related articles for article (PubMed ID: 21466419)
1. The severity of pseudohyperkalaemia is not dependent upon the stage of chronic kidney disease: a prospective study.
Imran M; Davison AS; Howse M; Williams P; Kemp GJ; Roberts NB
Clin Chem Lab Med; 2011 Jun; 49(6):1005-9. PubMed ID: 21466419
[TBL] [Abstract][Full Text] [Related]
2. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
3. Higher serum potassium level associated with late stage chronic kidney disease.
Hsieh MF; Wu IW; Lee CC; Wang SY; Wu MS
Chang Gung Med J; 2011; 34(4):418-25. PubMed ID: 21880197
[TBL] [Abstract][Full Text] [Related]
4. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.
Korgaonkar S; Tilea A; Gillespie BW; Kiser M; Eisele G; Finkelstein F; Kotanko P; Pitt B; Saran R
Clin J Am Soc Nephrol; 2010 May; 5(5):762-9. PubMed ID: 20203167
[TBL] [Abstract][Full Text] [Related]
5. [Pseudohyperkalemia in the serum in reactive thrombocytosis and thrombocythemia].
Mödder B; Meuthen I
Dtsch Med Wochenschr; 1986 Feb; 111(9):329-32. PubMed ID: 3948731
[TBL] [Abstract][Full Text] [Related]
6. Investigation of outpatients referred to a chemical pathologist with potential pseudohyperkalaemia.
Kapoor AK; Ravi A; Twomey PJ
J Clin Pathol; 2009 Oct; 62(10):920-3. PubMed ID: 19783721
[TBL] [Abstract][Full Text] [Related]
7. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
Alcázar Arroyo R
Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
[TBL] [Abstract][Full Text] [Related]
8. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
9. [Must we always treat hyperkalaemia?].
Basile C; Manobianca G; Bruno A; Tamma F
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832444
[TBL] [Abstract][Full Text] [Related]
10. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
11. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study.
Koren-Michowitz M; Avni B; Michowitz Y; Moravski G; Efrati S; Golik A
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):299-302. PubMed ID: 15133781
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
Maddirala S; Khan A; Vincent A; Lau K
Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
[TBL] [Abstract][Full Text] [Related]
13. Predictors of hyperkalemia and death in patients with cardiac and renal disease.
Jain N; Kotla S; Little BB; Weideman RA; Brilakis ES; Reilly RF; Banerjee S
Am J Cardiol; 2012 May; 109(10):1510-3. PubMed ID: 22342847
[TBL] [Abstract][Full Text] [Related]
14. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
15. Pseudohyperkalaemia is a common finding in myeloproliferative disorders that may lead to inappropriate management of patients.
Ong YL; Deore R; El-Agnaf M
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e151-7. PubMed ID: 19016918
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
[TBL] [Abstract][Full Text] [Related]
17. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
18. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.
McCullough PA; Beaver TM; Bennett-Guerrero E; Emmett M; Fonarow GC; Goyal A; Herzog CA; Kosiborod M; Palmer BF
Rev Cardiovasc Med; 2014; 15(1):11-23. PubMed ID: 24762462
[TBL] [Abstract][Full Text] [Related]
19. Pneumatic tube system transport and false hyperkalemia related to leukocytosis: a retrospective analysis.
Grzych G; Roland E; Lezier D; Beauvais D; Maboudou P; Lippi G
Ann Biol Clin (Paris); 2019 Jun; 77(3):281-286. PubMed ID: 31115339
[TBL] [Abstract][Full Text] [Related]
20. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Phakdeekitcharoen B; Leelasa-nguan P
Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
